Perindopril


Generic Medicine Info
Administration
Should be taken on an empty stomach (i.e. At least one hour before food or two hours after food).
Contraindications
History of angioedema related to previous ACE inhibitor treatment, hereditary or idiopathic angioedema, severe bilateral or unilateral renal stenosis, patients with extracorporeal treatments leading to contract of blooding with negatively charged surfaces. Concomitant use with aliskiren especially in patient with diabetes mellitus or renal impairment (GFR<60 mL/min/1.73 m2). Concomitant use with sacubitril/valsartan. Pregnancy and lactation.
Special Precautions
Patient with hypertrophic cardiomyopathy with outflow tract obstruction, salt or volume depletion, collagen vascular disease (e.g. SLE, scleroderma), severe mitral valve and aortic stenosis, ascites due to cirrhosis, refractory ascites, diabetes, primary aldosteronism, CV disease (e.g. ischaemic heart disease). Patients undergoing major surgery or during anaesthesia. Black race. Desensitisation treatment (e.g. hymenoptera venom). Renal and hepatic impairment. Elderly. Patient Counselling May impair ability to drive or operate machinery. Monitoring Parameters Monitor BP, BUN, serum K and creatinine levels, renal function, CBC with differential. Monitor for signs of angioedema and assess pregnancy status.
Adverse Reactions
Significant: Cholestatic jaundice, hypotension, syncope, hyperkalaemia, cough, neutropenia, agranulocytosis, anaemia, thrombocytopenia. Cardiac disorders: Palpitations, tachycardia. Ear and labyrinth disorders: Tinnitus. Eye disorders: Visual disturbance. Gastrointestinal disorders: Nausea, constipation, diarrhoea, dyspepsia, vomiting, abdominal pain. General disorders and administration site conditions: Asthenia, peripheral oedema. Immune system disorders: Urticaria. Investigations: Elevated BUN, increased serum creatinine, increased serum bilirubin. Musculoskeletal and connective tissue disorders: Muscle cramps. Nervous system disorders: Headache, paresthesia, vertigo, dysgeusia, dizziness. Psychiatric disorders: Mood disturbances, sleep disorders. Renal and urinary disorders: Renal insufficiency, proteinuria. Reproductive system and breast disorders: Erectile dysfunction. Respiratory, thoracic and mediastinal disorders: Dyspnoea, bronchospasm. Skin and subcutaneous tissue disorders: Pruritus, rash. Vascular disorders: Vasculitis, flushing, impaired peripheral circulation, epistaxis, Raynaud's phenomenon.
Potentially Fatal: Angioedema, arrhythmia. Rarely, fulminant hepatic necrosis.
Drug Interactions
Increased hypotensive effect with antihypertensive agents, diuretics, nitrates and baclofen. Increased risk of hyperkalaemia with K-sparing diuretics (e.g. spironolactone, eplerenone), K supplements, or other agents affecting serum K concentrations (e.g. trimethoprim, ciclosporin, heparin). May increase hypoglycaemic effect with insulin and oral hypoglycaemics agents. Increased risk of angioedema with mammalian target of rapamycin (mTOR) inhibitors (e.g. temsirolimus, sirolimus, everolimus), neutral endopeptidase (NEP) inhibitors (e.g. racecadotril), and dipeptidyl peptidase-IV (DPP-IV) inhibitors (e.g. sitagliptin, linagliptin). Concomitant use with NSAIDs including selective COX-2 inhibitors may result to renal function deterioration and reduced antihypertensive effect. May increase serum levels and toxicity of lithium. Coadministration with parenteral gold (e.g. Na aurothiomalate) may cause nitritoid reaction characterized by facial flushing, nausea, vomiting, and hypotension.
ATC Classification
C09AA04 - perindopril ; Belongs to the class of ACE inhibitors. Used in the treatment of cardiovascular disease.
Disclaimer: This information is independently developed by CIMS based on perindopril from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in